Amicus’ Pompe disease therapy joins early access scheme
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
Read More
Tag: Amicus
Amicus’ Galafold wins US approval
Amicus Therapeutics’ Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease.
Read More
Final NICE yes for Amicus’ Fabry disease drug
Cost regulators for NHS therapies in England and Wales have now published final guidelines endorsing the use of Amicus Therapeutics’ Galafold for treating the rare genetic disorder Fabry disease.
Read More
NICE backs Amicus’ Galafold for Fabry disease
The National Institute for Health and Care Excellence is backing National Health Service use of Amicus Therapeutics’ Galafold for treating the rare genetic disorder Fabry disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
